Nextech Invest — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.
BiotechBoston, US
Alan Huang(Executive Officer)Adam Crystal(Executive Officer)Daniella Beckman(Executive Officer)Douglas Barry(Executive Officer)Aaron Davis(Director)
BoardBarbara Weber(Executive Officer, Director)in
Board seatKanishka Pothula· per SEC Form D
Co-investorsForesite CapitalNSG VenturesThird Rock Ventures
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)Josh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesMission BiocapitalMRL Ventures FundInkefRA Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.